Cargando…

The expression of RUNX3 in colorectal cancer is associated with disease stage and patient outcome

RUNX3 is believed to have tumour suppressor properties in several cancer types. Inactivation of RUNX3 has been shown to occur by methylation-induced transcriptional silencing and by mislocalization of the protein to the cytoplasm. The aim of this study was to examine the clinical significance of RUN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soong, R, Shah, N, Peh, B K, Chong, P Y, Ng, S S, Zeps, N, Joseph, D, Salto-Tellez, M, Iacopetta, B, Ito, Y
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653772/ https://www.ncbi.nlm.nih.gov/pubmed/19223906 http://dx.doi.org/10.1038/sj.bjc.6604899

Ejemplares similares

Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients
por: Morris, M, et al.
Publicado: (2007)

RUNX3 is oncogenic in natural killer/T-cell lymphoma and is transcriptionally regulated by MYC
por: Selvarajan, V, et al.
Publicado: (2017)

Screen-detected colorectal cancers are associated with an improved outcome compared with stage-matched interval cancers
por: Gill, M D, et al.
Publicado: (2014)

Preoperative computed tomography staging of nonmetastatic colon cancer predicts outcome: implications for clinical trials
por: Smith, N J, et al.
Publicado: (2007)

Outcomes after radical hysterectomy in patients with early-stage adenocarcinoma of uterine cervix
por: Park, J-Y, et al.
Publicado: (2010)

Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status
por: Watkins, D J, et al.
Publicado: (2010)

Prolyl isomerase Pin1 down-regulates tumor suppressor RUNX3 in breast cancer
por: Tsang, Ying-Hung Nicole, et al.
Publicado: (2012)

The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer
por: Winton, E de, et al.
Publicado: (2009)

The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress?
por: Chan, J K, et al.
Publicado: (2008)

Time from first presentation in primary care to treatment of symptomatic colorectal cancer: effect on disease stage and survival
por: Murchie, P, et al.
Publicado: (2014)

Comparison of TNM staging systems for nasopharyngeal carcinoma, and proposal of a new staging system
por: OuYang, P-Y, et al.
Publicado: (2013)

Abnormal expression of TRIB3 in colorectal cancer: a novel marker for prognosis
por: Miyoshi, N, et al.
Publicado: (2009)

Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy
por: Lee, D-W, et al.
Publicado: (2013)

Adenosine triphosphate-based chemotherapy response assay-guided chemotherapy in unresectable colorectal liver metastasis
por: Hur, H, et al.
Publicado: (2012)

Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study
por: Bork, U, et al.
Publicado: (2015)

Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer
por: Hao, T B, et al.
Publicado: (2014)

A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens
por: Jeung, H-C, et al.
Publicado: (2006)

Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer
por: Lu, C-Y, et al.
Publicado: (2013)

Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Chong, G, et al.
Publicado: (2005)

Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial
por: Mochizuki, I, et al.
Publicado: (2012)

Positive lymph node retrieval ratio optimises patient staging in colorectal cancer
por: Moug, S J, et al.
Publicado: (2009)

Long-term outcomes of patients with 10 or more colorectal liver metastases
por: Allard, M A, et al.
Publicado: (2017)

Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer
por: Yoshioka, T, et al.
Publicado: (2009)

Genetic factors associated with intestinal metaplasia in a high risk Singapore-Chinese population: a cohort study
por: Zhu, Feng, et al.
Publicado: (2009)

The beneficial effect of palliative resection in metastatic colorectal cancer
por: Park, J H, et al.
Publicado: (2013)

Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer
por: Hong, Y S, et al.
Publicado: (2006)

Side effects during chemotherapy predict tumour response in advanced colorectal cancer
por: Schuell, B, et al.
Publicado: (2005)

Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab
por: Zulato, E, et al.
Publicado: (2014)

Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer
por: Ng, K, et al.
Publicado: (2009)

The prognostic value of the stem-like group in colorectal cancer using a panel of immunohistochemistry markers
por: Ong, Chee Wee, et al.
Publicado: (2015)

Effect of portal vein embolisation on the growth rate of colorectal liver metastases
por: Pamecha, V, et al.
Publicado: (2009)

Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I–III nonsmall cell lung cancer
por: Kaira, K, et al.
Publicado: (2008)

Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer
por: Yamada, Y, et al.
Publicado: (2008)

Pre-diagnostic NSAID use but not hormone therapy is associated with improved colorectal cancer survival in women
por: Coghill, A E, et al.
Publicado: (2011)

A pilot randomised controlled trial to reduce colorectal cancer risk markers associated with B-vitamin deficiency, insulin resistance and colonic inflammation
por: Bruce, W R, et al.
Publicado: (2005)

Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature
por: Des Guetz, G, et al.
Publicado: (2006)

Prognostic Impact of the Number of Examined Lymph Nodes in Stage II Colorectal Adenocarcinoma: A Retrospective Study
por: Lei, Purun, et al.
Publicado: (2020)

Loss of tumoral expression of soluble IL-6 receptor is associated with disease progression in colorectal cancer
por: Okugawa, Y, et al.
Publicado: (2010)

Comparisons of vaginal and abdominal radical trachelectomy for early-stage cervical cancer: preliminary results of a multi-center research in China
por: Cao, D Y, et al.
Publicado: (2013)

Gene expression profiling of colorectal adenomas and early invasive carcinomas by cDNA array analysis
por: Nosho, K, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_dnrtnl5gho669l5p5kd71p68t4